Cancers
Cancers is published by Multidisciplinary Digital Publishing Institute. This page lists its abbreviations and what the registries record about it. It also shows how to cite one of its articles in 12 styles.
What the registries record
Cancers is listed under the ISSN 2072-6694.
| Fact | Record | Source |
|---|---|---|
| Publisher | Multidisciplinary Digital Publishing Institute | OpenAlex |
| Open access | Open access, per OpenAlex | OpenAlex |
| Listed in DOAJ | Not listed in DOAJ, per OpenAlex | OpenAlex |
| Article processing charge | $3,499 per article | OpenAlex |
| 2-year mean citedness | 6.13 | OpenAlex |
| h-index | 241 | OpenAlex |
| Indexed in MEDLINE | Not listed as indexed in MEDLINE, per NLM | NLM |
| NLM abbreviation | Cancers (Basel) | NLM |
| ISO 4 abbreviation | Cancers | LTWA |
The Journal Impact Factor is Clarivate's figure, and this page does not show it.
This page records facts and never judges a journal. A journal missing from an index can still be sound.
The figures are a snapshot taken on 2026-11-19, so a registry may have changed since.
Abbreviations
NLM gives "Cancers (Basel)" and ISO 4 gives "Cancers". A style that shortens journal names may use its own list, so a reference on this page can differ from the forms above.
How to cite an article from Cancers
The sample is one article of the journal. Its title is "Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study". Its DOI is 10.3390/cancers11081084. CiteTools wrote each reference from the Crossref record.
APA Style
Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., Takenaka, M., Sakurai, T., Watanabe, T., Morita, M., Ogawa, C., Wada, Y., Ikeda, M., Ishii, H., Izumi, N., & Nishida, N. (2019). Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child–Pugh A liver function: A proof-of-concept study. Cancers, 11(8), Article 1084. https://doi.org/10.3390/cancers11081084
MLA Style
Kudo, Masatoshi, et al. “Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study.” Cancers, vol. 11, no. 8, July 2019, 1084, https://doi.org/10.3390/cancers11081084.
Chicago Style
Kudo, Masatoshi, Kazuomi Ueshima, Stephan Chan, et al. “Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study.” Cancers 11, no. 8 (2019): 1084. https://doi.org/10.3390/cancers11081084.
Harvard Referencing
Kudo, M. et al. (2019) ‘Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study’, Cancers, 11(8), 1084. Available at: https://doi.org/10.3390/cancers11081084.
IEEE Style
M. Kudo et al., “Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study,” Cancers, vol. 11, no. 8, Art. no. 1084, Jul. 2019, doi: 10.3390/cancers11081084.
Vancouver Style
Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child–Pugh A liver function: a proof-of-concept study. Cancers (Basel). 2019 Jul 31;11(8):1084. doi:10.3390/cancers11081084.
AMA Style
Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child–Pugh A liver function: a proof-of-concept study. Cancers (Basel). 2019;11(8):1084. doi:10.3390/cancers11081084
ACS Style
Kudo, M.; Ueshima, K.; Chan, S.; Minami, T.; Chishina, H.; Aoki, T.; Takita, M.; Hagiwara, S.; Minami, Y.; Ida, H.; Takenaka, M.; Sakurai, T.; Watanabe, T.; Morita, M.; Ogawa, C.; Wada, Y.; Ikeda, M.; Ishii, H.; Izumi, N.; Nishida, N. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study. Cancers 2019, 11 (8), 1084. DOI: 10.3390/cancers11081084
CSE Style
Kudo M et al. 2019. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child–Pugh A liver function: a proof-of-concept study. Cancers. 11(8):1084. https://doi.org/10.3390/cancers11081084
ASA Style
Kudo, Masatoshi, Kazuomi Ueshima, Stephan Chan, Tomohiro Minami, Hirokazu Chishina, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Yoshiyuki Wada, Masafumi Ikeda, Hiroshi Ishii, Namiki Izumi, and Naoshi Nishida. 2019. “Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study.” Cancers 11(8):1084. doi:10.3390/cancers11081084.
APSA Style
Kudo, Masatoshi, Kazuomi Ueshima, Stephan Chan, Tomohiro Minami, Hirokazu Chishina, Tomoko Aoki, Masahiro Takita, et al. 2019. “Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study.” Cancers 11 (8): 1084. doi: 10.3390/cancers11081084.
OSCOLA
Kudo M and others, ‘Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-to-Seven Criteria and Child–Pugh A Liver Function: A Proof-of-Concept Study’ (2019) 11 Cancers 1084 <https://doi.org/10.3390/cancers11081084>
Frequently asked questions
What is the abbreviation of Cancers?
NLM gives "Cancers (Basel)" and ISO 4 gives "Cancers". The ISO 4 form is written from the LTWA rules. A style that shortens journal names may use its own list, so a reference on this page can differ from the forms above.
How do I cite an article from Cancers?
Paste the DOI of the article into the CiteTools list and choose a style. The 12 references above show one article in every style.
Where do the facts on this page come from?
OpenAlex gives the publisher, access, DOAJ, charge, citedness and h-index figures. NLM gives MEDLINE indexing and its abbreviation. The LTWA rules give the ISO 4 form.
Related pages
Check and abbreviate journals
Cite in your style
Other journals
- Nature Communications
- Scientific Reports
- Proceedings of the National Academy of Sciences
- Nature
- PLoS ONE
- New England Journal of Medicine
- Science
- Cell
- Journal of the American Chemical Society
- eLife
- Nucleic Acids Research
- JAMA Network Open
- Nature Medicine
- ACS Nano
- The Lancet
- Advanced Materials
- International Journal of Molecular Sciences
- JAMA
- Frontiers in Immunology
- Angewandte Chemie International Edition
- Circulation
- Cureus
- Brain
- Neurology
- Chemical Engineering Journal
- BMC Public Health
- Heliyon
- IEEE Access
- Journal of Medical Internet Research